Dados do Trabalho
USE OF A SLOW-RELEASE INTRAVITREAL CLINDAMYCIN IMPLANT FOR THE MANAGEMENT OF OCULAR TOXOPLASMOSIS: CLINICAL FOLLOW-UP
Introdução / Purpose
To verify the safety of intravitreal clindamycin implant for ocular toxoplasmosis in patients that are intolerant or do not respond to traditional treatment
Material e Método / Methods
Phase I clinical trial to evaluate the safety of a 0.3 mgintravitreal implant of clindamycin. All patients with active ocular toxoplasmic retinochoroiditis18-years old or older that had intolerance and/or did not respond to traditional oral treatment were invited to participate.. Comprehensive ophthalmologic evaluation was performed before intravitreal implant insertionand included ETDRS best-corrected visual acuity (BCVA),SD-optical coherence tomography (SD-OCT) and electroretinogram (ERG). The same tests were also performedone , three and six months after the procedure.The main safety parameters included changes in ERG wave amplitudes, eye inflammation and BCVA.
Resultados / Results
We reported here patients operated with the intravitreal clindamycin implant for ocular toxoplasmosis. Of the 4 cases reported, 2obtained anatomical and functional success, 1 patient lost follow-up and 1 patient demonstrated no anatomic and functional improvement, due to a poor prognosis. There were no significant changes in electroretinography waves after treatment with the implant
Discussão e Conclusões / Conclusion
The present study describes the first study of intravitreal clindamycin implant for ocular toxoplasmosis in intolerant or refractory patients. This technique was safe and associated with anatomic and visual improvement in most cases.
ocular toxoplasmosis, intravitreal clindamycin implant
IGOR COELHO, ARMANDO CUNHA, ANDRÉ MESSIAS, GABRIELLA CUNHA, SILVIA FIALHO, JOÃO MARCELO FURTADO, RODRIGO JORGE, JOÃO PEDRO BRAGA, MOISES LUCENA, LETICIA AUDI, THAIS BASTOS, RENATO BREDARIOL, JULIANA VIEIRA